---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-014809"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:23:00.767271+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics receives Nasdaq delisting notice for stockholders' equity below $2.5M minimum

## Summary
- Stockholders' equity was $2.2M as of Dec 31, 2024, below the $2.5M minimum required by Nasdaq Listing Rule 5550(b)(1).
- Company must submit a compliance plan to Nasdaq by May 3, 2024.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- No immediate effect on listing; common stock continues trading under ERNA.

## SEC filing metadata
- accession: 0001140361-24-014809
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036124014809/0001140361-24-014809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036124014809/ef20024913_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-014809
- JSON: https://secwatch.observer/filing/0001140361-24-014809.json
- Plain text: https://secwatch.observer/filing/0001140361-24-014809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.